AUTOTAC

AUTOTAC Bio, Inc. is a new drug development company based on the AUTOTAC (autophagy-targeting chimera) protein target degradation platform technology. AUTOTAC is a next-generation new drug development platform technology that can selectively send various pathogenic substances into autophagy, induce lysosomal degradation, and thereby eliminate pathogenic substances, including those related to cancer, degenerative brain diseases, autoimmune disorders, and coronaviruses.